IBDEI040 ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,1342,1,4,0)
 ;;=4^Z79.01
 ;;^UTILITY(U,$J,358.3,1342,2)
 ;;=^5063330
 ;;^UTILITY(U,$J,358.3,1343,0)
 ;;=Z95.1^^3^40^1
 ;;^UTILITY(U,$J,358.3,1343,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1343,1,3,0)
 ;;=3^Presence of aortocoronary bypass graft
 ;;^UTILITY(U,$J,358.3,1343,1,4,0)
 ;;=4^Z95.1
 ;;^UTILITY(U,$J,358.3,1343,2)
 ;;=^5063669
 ;;^UTILITY(U,$J,358.3,1344,0)
 ;;=Z95.2^^3^40^3
 ;;^UTILITY(U,$J,358.3,1344,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1344,1,3,0)
 ;;=3^Presence of prosthetic heart valve
 ;;^UTILITY(U,$J,358.3,1344,1,4,0)
 ;;=4^Z95.2
 ;;^UTILITY(U,$J,358.3,1344,2)
 ;;=^5063670
 ;;^UTILITY(U,$J,358.3,1345,0)
 ;;=Z95.3^^3^40^4
 ;;^UTILITY(U,$J,358.3,1345,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1345,1,3,0)
 ;;=3^Presence of xenogenic heart valve
 ;;^UTILITY(U,$J,358.3,1345,1,4,0)
 ;;=4^Z95.3
 ;;^UTILITY(U,$J,358.3,1345,2)
 ;;=^5063671
 ;;^UTILITY(U,$J,358.3,1346,0)
 ;;=Z95.0^^3^40^2
 ;;^UTILITY(U,$J,358.3,1346,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1346,1,3,0)
 ;;=3^Presence of cardiac pacemaker
 ;;^UTILITY(U,$J,358.3,1346,1,4,0)
 ;;=4^Z95.0
 ;;^UTILITY(U,$J,358.3,1346,2)
 ;;=^5063668
 ;;^UTILITY(U,$J,358.3,1347,0)
 ;;=A15.0^^3^41^103
 ;;^UTILITY(U,$J,358.3,1347,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1347,1,3,0)
 ;;=3^Tuberculosis of lung
 ;;^UTILITY(U,$J,358.3,1347,1,4,0)
 ;;=4^A15.0
 ;;^UTILITY(U,$J,358.3,1347,2)
 ;;=^5000062
 ;;^UTILITY(U,$J,358.3,1348,0)
 ;;=A31.0^^3^41^92
 ;;^UTILITY(U,$J,358.3,1348,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1348,1,3,0)
 ;;=3^Pulmonary mycobacterial infection
 ;;^UTILITY(U,$J,358.3,1348,1,4,0)
 ;;=4^A31.0
 ;;^UTILITY(U,$J,358.3,1348,2)
 ;;=^5000149
 ;;^UTILITY(U,$J,358.3,1349,0)
 ;;=B20.^^3^41^72
 ;;^UTILITY(U,$J,358.3,1349,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1349,1,3,0)
 ;;=3^Human immunodeficiency virus [HIV] disease
 ;;^UTILITY(U,$J,358.3,1349,1,4,0)
 ;;=4^B20.
 ;;^UTILITY(U,$J,358.3,1349,2)
 ;;=^5000555
 ;;^UTILITY(U,$J,358.3,1350,0)
 ;;=B02.9^^3^41^110
 ;;^UTILITY(U,$J,358.3,1350,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1350,1,3,0)
 ;;=3^Zoster without complications
 ;;^UTILITY(U,$J,358.3,1350,1,4,0)
 ;;=4^B02.9
 ;;^UTILITY(U,$J,358.3,1350,2)
 ;;=^5000501
 ;;^UTILITY(U,$J,358.3,1351,0)
 ;;=A60.9^^3^41^26
 ;;^UTILITY(U,$J,358.3,1351,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1351,1,3,0)
 ;;=3^Anogenital herpesviral infection, unspecified
 ;;^UTILITY(U,$J,358.3,1351,1,4,0)
 ;;=4^A60.9
 ;;^UTILITY(U,$J,358.3,1351,2)
 ;;=^5000359
 ;;^UTILITY(U,$J,358.3,1352,0)
 ;;=A60.04^^3^41^71
 ;;^UTILITY(U,$J,358.3,1352,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1352,1,3,0)
 ;;=3^Herpesviral vulvovaginitis
 ;;^UTILITY(U,$J,358.3,1352,1,4,0)
 ;;=4^A60.04
 ;;^UTILITY(U,$J,358.3,1352,2)
 ;;=^5000356
 ;;^UTILITY(U,$J,358.3,1353,0)
 ;;=A60.01^^3^41^70
 ;;^UTILITY(U,$J,358.3,1353,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1353,1,3,0)
 ;;=3^Herpesviral infection of penis
 ;;^UTILITY(U,$J,358.3,1353,1,4,0)
 ;;=4^A60.01
 ;;^UTILITY(U,$J,358.3,1353,2)
 ;;=^5000353
 ;;^UTILITY(U,$J,358.3,1354,0)
 ;;=B00.81^^3^41^69
 ;;^UTILITY(U,$J,358.3,1354,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1354,1,3,0)
 ;;=3^Herpesviral hepatitis
 ;;^UTILITY(U,$J,358.3,1354,1,4,0)
 ;;=4^B00.81
 ;;^UTILITY(U,$J,358.3,1354,2)
 ;;=^5000478
 ;;^UTILITY(U,$J,358.3,1355,0)
 ;;=B15.9^^3^41^68
 ;;^UTILITY(U,$J,358.3,1355,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1355,1,3,0)
 ;;=3^Hepatitis A without hepatic coma
 ;;^UTILITY(U,$J,358.3,1355,1,4,0)
 ;;=4^B15.9
 ;;^UTILITY(U,$J,358.3,1355,2)
 ;;=^5000536
 ;;^UTILITY(U,$J,358.3,1356,0)
 ;;=B16.9^^3^41^5
 ;;
 ;;$END ROU IBDEI040
